Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2
Díaz-Troyano, Noelia (Universitat Autònoma de Barcelona)
Gabriel-Medina, Pablo (Universitat Autònoma de Barcelona)
Weber, Stephen (Roche Diagnostics GmbH (Penzberg, Alemanya))
Klammer, Martin (Roche Diagnostics GmbH (Penzberg, Alemanya))
Barquín-DelPino, Raquel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Castillo-Ribelles, Laura (Universitat Autònoma de Barcelona)
Esteban, Àngels (Hospital Universitari Vall d'Hebron)
Hernández-González, Manuel (Universitat Autònoma de Barcelona)
Ferrer Costa, Roser (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Pumarola Suñé, Tomàs (Universitat Autònoma de Barcelona)
Rodríguez Frías, Francisco (Universitat Autònoma de Barcelona)

Data:	2022
Resum:	Predicting disease severity in patients infected with SARS-CoV-2 is difficult. Soluble angiotensin-converting enzyme 2 (sACE2) arises from the shedding of membrane ACE2 (mACE2), which is a receptor for SARS-CoV-2 spike protein. We evaluated the predictive value of sACE2 compared with known biomarkers of inflammation and tissue damage (CRP, GDF-15, IL-6, and sFlt-1) in 850 patients with and without SARS-CoV-2 with different clinical outcomes. For univariate analyses, median differences between biomarker levels were calculated for the following patient groups (classified by clinical outcome): RT-PCR-confirmed SARS-CoV-2 positive (Groups 1-4); RT-PCR-confirmed SARS-CoV-2 negative following previous SARS-CoV-2 infection (Groups 5 and 6); and 'SARS-CoV-2 unexposed' patients (Group 7). Median levels of CRP, GDF-15, IL-6, and sFlt-1 were significantly higher in hospitalized patients with SARS-CoV-2 compared with discharged patients (all p < 0. 001), whereas levels of sACE2 were significantly lower (p < 0. 001). ROC curve analysis of sACE2 provided cut-offs for predicting hospital admission (≤0. 05 ng/mL (positive predictive value: 89. 1%) and ≥0. 42 ng/mL (negative predictive value: 84. 0%)). These findings support further investigation of sACE2, as a single biomarker or as part of a panel, to predict hospitalization risk and disease severity in patients with SARS-CoV-2 infection.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Disease severity ; COVID-19 ; SARS-CoV-2 ; Angiotensin-converting enzyme 2 ; SARS-CoV-2 spike protein ; Biomarkers ; Inflammation
Publicat a:	Diagnostics, Vol. 12 (april 2022) , ISSN 2075-4418

DOI: 10.3390/diagnostics12040886
PMID: 35453934

16 p, 2.7 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats